Finance

Beta
Lists
NUZ:ASX
Neurizon Therapeutics Ltd
A$0.060
-1.64%
(-0.0010) 1D
Jun 5, 4:10:02 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for NUZ...
Open
A$0.06
High
A$0.06
Low
A$0.06
Mkt. cap
45.99M
Avg. vol.
641.44K
Volume
975.11K
52-wk high
A$0.18
52-wk low
A$0.06
EPS
-A$0.03
Shares outstanding
753.98M
No. of employees
52
Open
A$0.06
High
A$0.06
Low
A$0.06
Mkt. cap
45.99M
Avg. vol.
641.44K
Volume
975.11K
52-wk high
A$0.18
52-wk low
A$0.06
EPS
-A$0.03
Shares outstanding
753.98M
No. of employees
52
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to NUZ in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for NUZ in the last 3 months.
Highest
Current A$0.06
A$0.20 (+233.77%)
Average
A$0.20 (+226.67%)
Lowest
A$0.20 (+233.77%)
News stories
From sources across the web
About Neurizon Therapeutics Ltd
CEO-
Employees52
Founded2000
Headquarters-
SectorPharmaceutical industry
Websiteneurizon.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
3.20K
3.20K
2.99M
2.99M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
3.02M
3.02M
4.12M
4.12M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.54M
1.54M
1.40M
1.40M
Operating expense
4.72M
4.72M
5.70M
5.70M
Total operating expenses
4.72M
4.72M
5.70M
5.70M
Operating income
-4.72M
-4.72M
-2.72M
-2.72M
Other non operating income
-
-
-
-
EBT including unusual items
-4.66M
-4.66M
-2.77M
-2.77M
EBT excluding unusual items
-4.66M
-4.66M
-2.77M
-2.77M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.66M
-4.66M
-2.77M
-2.77M
Net profit margin
-145,620.04%
-145,620.04%
-92.70%
-92.70%
Earnings per share
-
-
-
-
Interest and investment income
59.80K
59.80K
11.89K
11.89K
Interest expense
-
-
-63.39K
-63.39K
Net interest expenses
59.80K
59.80K
-51.50K
-51.50K
Depreciation and amortization charges
22.00
22.00
359.00
359.00
EBITDA
-4.72M
-4.72M
-2.72M
-2.72M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer